antibody

Polyclonal Antibody to Suppressors Of Cytokine Signaling 1 (SOCS1)

MBS2090522

0.01 mg

110 USD

polyclonal

rabbit

nonconjugated

western blot, immunohistochemistry, immunocytochemistry, immunoprecipitation

Antibody

Polyclonal Antibody to Suppressors Of Cytokine Signaling 1 (SOCS1)

[Suppressors Of Cytokine Signaling 1 (SOCS1)]

[CIS1; CISH1; JAB; SOCS-1; SSI-1; SSI1; TIP3; JAK-binding protein; STAT-induced STAT inhibitor 1; Tec-interacting protein 3]

[suppressor of cytokine signaling 1; Suppressor of cytokine signaling 1; suppressor of cytokine signaling 1; suppressor of cytokine signaling 1; JAK-binding protein; JAB; STAT-induced STAT inhibitor 1; SSI-1; Tec-interacting protein 3; TIP-3]

[SOCS1]

[SOCS1; SOCS1; JAB; CIS1; SSI1; TIP3; CISH1; SSI-1; TIP-3; SOCS-1; SSI1; TIP3; SOCS-1; JAB; SSI-1; TIP-3]

Polyclonal

Rabbit

Antigen-specific affinity chromatography followed by Protein A affinity chromatography

Supplied as solution form in PBS, pH7.4, containing 0.02% NaN3, 50% glycerol.

1 mg/ml

Storage: Avoid repeated freeze/thaw cycles. Store at 4ºC for frequent use. Aliquot and store at -20ºC for 12 months. Stability Test: The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.

Western Blot (WB), Immunohistochemistry (IHC), Immunocytochemistry (ICC), Immunoprecipitation (IP).

Western blotting: 0.5-2 ug/mL;1:500-2000. Immunohistochemistry: 5-20 ug/mL;1:50-200. Immunocytochemistry: 5-20 ug/mL;1:50-200. Optimal working dilutions must be determined by end user

Western Blot (WB)

Organism Species: Homo sapiens (Human). Source: Polyclonal antibody preparation. Traits: Liquid. Immunogen: Recombinant SOCS1 (Met1~Ile211) expressed in E.coli

4507233

NP_003736.1

NM_003745.1

O15524

Adaptive Immune System Pathway (366160); Adipogenesis Pathway (198832); Antigen Processing: Ubiquitination Proteasome Degradation Pathway (366162); Class I MHC Mediated Antigen Processing Presentation Pathway (366161); Cytokine Signaling In Immune System Pathway (366171); ECS Complex Pathway (413455); ECS Complex Pathway (468394); EGFR1 Signaling Pathway (198782); EPO Receptor Signaling Pathway (198882); Growth Hormone Receptor Signaling Pathway (477128)

This gene encodes a member of the STAT-induced STAT inhibitor (SSI), also known as suppressor of cytokine signaling (SOCS), family. SSI family members are cytokine-inducible negative regulators of cytokine signaling. The expression of this gene can be induced by a subset of cytokines, including IL2, IL3 erythropoietin (EPO), CSF2/GM-CSF, and interferon (IFN)-gamma. The protein encoded by this gene functions downstream of cytokine receptors, and takes part in a negative feedback loop to attenuate cytokine signaling. Knockout studies in mice suggested the role of this gene as a modulator of IFN-gamma action, which is required for normal postnatal growth and survival. [provided by RefSeq, Jul 2008]

SOCS1: SOCS family proteins form part of a classical negative feedback system that regulates cytokine signal transduction. SOCS1 is involved in negative regulation of cytokines that signal through the JAK/STAT3 pathway. Through binding to JAKs, inhibits their kinase activity. In vitro, also suppresses Tec protein- tyrosine activity. Appears to be a major regulator of signaling by interleukin 6 (IL6) and leukemia inhibitory factor (LIF). Regulates interferon-gamma mediated sensory neuron survival. Probable substrate recognition component of an ECS (Elongin BC-CUL2/5-SOCS-box protein) E3 ubiquitin ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins. Seems to recognize JAK2. SOCS1 appears to be a negative regulator in IGF1R signaling pathway. Interacts with multiple activated signaling proteins of the tyrosine kinase signaling pathway including JAK family kinases, TEC, KIT, GRB2 and VAV. Binding to JAKs is mediated through the KIR and SH2 domains to a phosphorylated tyrosine residue within the JAK JH1 domain. Binds the SH3 domain of GRB2 via diproline determinants in the N-terminus, and the N-terminal regulatory domain of VAV. Interacts with the Elongin BC complex (TCEB1 and TCEB2). Component of an ECS CBC(SOCS1) E3 ubiquitin-protein ligase complex which contains Elongin BC, CUL5, RBX1 and SOCS1. Interacts (via SH2 domain and SOCS box) with TRIM8. Interacts with AXL, CUL2 and FGFR3. Interacts with INSR. By a subset of cytokines including those belonging to the interferon, interleukin and colony-stimulating factor families. Expressed in all tissues with high expression in spleen, small intestine and peripheral blood leukocytes. Protein type: Inhibitor. Chromosomal Location of Human Ortholog: 16p13.13. Cellular Component: cytoplasm; cytoplasmic ribonucleoprotein granule; cytoplasmic vesicle; cytosol; nucleoplasm. Molecular Function: insulin-like growth factor receptor binding; kinase inhibitor activity; protein binding; protein kinase binding; protein kinase inhibitor activity. Biological Process: cytokine-mediated signaling pathway; fat cell differentiation; interleukin-7-mediated signaling pathway; JAK-STAT cascade; negative regulation of insulin receptor signaling pathway; negative regulation of JAK-STAT cascade; negative regulation of protein kinase activity; negative regulation of tyrosine phosphorylation of STAT protein; positive regulation of regulatory T cell differentiation; protein ubiquitination; regulation of activation of Janus kinase activity; regulation of cytokine secretion; regulation of growth; regulation of protein amino acid phosphorylation

0.01 mg

110 USD

0.02 mg

130

0.05 mg

175

0.1 mg

225

0.2 mg

340

1 mg

800